Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2023-11-23 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
职工代表监事任命公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the appointment of a new employee representative supervisor (监事) due to the resignation of the previous one. It details the election process, the new appointee's background, and the impact of the appointment on the company governance. There are no financial statements, earnings data, or report publications. The content focuses on changes in the company's supervisory board members, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2023-11-23 Chinese
关于重组九价人乳头瘤病毒疫苗于印度尼西亚启动Ⅲ期临床试验及受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the initiation of Phase III clinical trials for a recombinant nine-valent human papillomavirus vaccine in Indonesia. It includes details about regulatory approval from the Indonesian Food and Drug Authority and the enrollment of the first subject. The document is short (838 characters) and serves as a progress update on clinical trials rather than a financial report or detailed regulatory filing. It does not contain financial data, management changes, voting results, or other report types. It is a regulatory announcement about clinical trial progress, fitting best under Regulatory Filings (RNS).
2023-11-21 Chinese
解除股权质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the dates involved, and the current status of pledged shares. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like Share Issue/Capital Change or Director's Dealing. The document length is short and it is an announcement, not a report or detailed filing.
2023-10-31 Chinese
回购进展情况公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding the progress of a share repurchase (buyback) plan by the company Beijing 康乐卫士生物技术股份有限公司. It details the board and shareholder approvals, the purpose of the buyback, pricing, quantity, funding sources, implementation period, and current progress (no shares repurchased yet). The document is titled as a "回购进展情况公告" which translates to "Repurchase Progress Announcement." It does not contain financial statements or detailed financial analysis but is an update on the company's share repurchase activity. According to the filing definitions, reports about share repurchase activities fall under "Transaction in Own Shares (POS)." The document length is 1755 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is POS with high confidence.
2023-10-31 Chinese
第四届监事会第二十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the supervisory board of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the convening and attendance of the supervisory board meeting and the approval of the company's 2023 third quarter report. The document does not contain the actual financial data or the full quarterly report but references that the full 2023 third quarter report is disclosed on the Beijing Stock Exchange information platform. The document is short (796 characters) and serves as an announcement of the meeting resolution and approval of the quarterly report, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice rather than an Interim/Quarterly Report (IR).
2023-10-29 Chinese
第四届董事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 25th meeting of the 4th Board of Directors of Beijing Kangle Weishi Biotechnology Co., Ltd. It includes details about the meeting's time, place, attendance, and the approval of the company's 2023 third quarter report. The document states that the third quarter report has been prepared and disclosed on the Beijing Stock Exchange information platform, but the document itself does not contain the report or detailed financial data. It is an announcement of the board meeting resolutions, specifically the approval of the quarterly report, rather than the report itself. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management information.
2023-10-29 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.